FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC Biotherapeutics, Inc. (“GTC”, Nasdaq: GTCB) total net loss for the first quarter of 2008 was $8.2 million, or $0.10 per share, compared with $7.5 million, or $0.10 per share, in the first quarter of 2007. Revenue and expenses were both reduced from the prior period, primarily due to the timing of supplying product in the ATryn® program. Additional delivery of ATryn® to LEO Pharma A/S, GTC’s commercial and development partner for Europe, Canada, and the Middle East, is planned for the second quarter of 2008.
